Interferon beta, a biologic response modifying medication, is commonly prescribed in cases of multiple sclerosis (MS) and until recently associated to delays in the progression of the disease. The injectable drug is a synthetic version of a naturally occurring protein, according to the National Library of Medicine.

In a recent study published in the Journal of the American Medical Association, evidence indicates Interferon beta does not delay the progression of MS as previously thought. It does, however, reduce flare-ups, which warrants continued usage according to researchers.

Interferon beta, a biologic response modifying medication, is commonly prescribed in cases of multiple sclerosis (MS) and until recently associated to delays in the progression of the disease. The injectable drug is a synthetic version of a naturally occurring protein, according to the National Library of Medicine.

In a recent study published in the Journal of the American Medical Association, evidence indicates Interferon beta does not delay the progression of MS as previously thought. It does, however, reduce flare-ups, which warrants continued usage according to researchers.